NCT04715321UnknownNot Applicable
Computed Tomography Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma: A Prospective Study
Sun Yat-sen University1 site in 1 country120 target enrollmentStarted: February 15, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Predictive performance of CT perfusion
Study Overview
Brief Summary
Distinct vascular patterns (ECTC or Non-ECTC) of tumors plays an important role in tumor migration, metastasis and drug resistant in hepatocellular carcinoma (HCC). However, there is no non-invasive method to predict vascular pattern in clinical. In the present study, we prospectively assess CT perfusion parameters for evaluation of the vascular pattern in HCC.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •age over than 18 years old
- •tumor size of less than 5 cm
- •Child-Pugh A class liver function
- •an Eastern Cooperative Oncology Group performance status of 0
- •no previous treatment for HCC
- •pathological diagnosis of hepatocellular carcinoma
- •adequate organ function (white blood cell count ≥3.0 × 109/L, absolute neutrophil count ≥1.5 × 109/L, platelet count ≥75 × 109/L, aspartate transaminase and alanine transaminase≤5 × upper limit of the normal, creatinine clearance rate of ≤1.5 × upper limit of the normal, and left ventricular ejection ≥45%)
Exclusion Criteria
- •Patients who received antitumor therapy before recurrence, including radiotherapy, transarterial chemoembolization, tyrosine kinase inhibitor, and immune checkpoint inhibitor
- •a known medical history of HIV infection
- •pregnancy or breastfeeding
- •portal vein tumor thrombosis or hepatic vein thrombosis detected by any routine imaging modality, including ultrasonography, dynamic contrast CT and MRI
- •any evidence of tumor metastasis or prior recurrence
- •hepatic decompensation
Outcomes
Primary Outcomes
Predictive performance of CT perfusion
Time Frame: 6 months
The primary outcome of our study is to evaluate the sensitivity and specifity of CT perfusion in predicting vascular pattern of HCC
Secondary Outcomes
- Disease-free survival (DFS)(6 months)
- Overall survival (OS)(6 months)
Investigators
Shi Ming
Professor
Sun Yat-sen University
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer PatientsBreast NeoplasmsNeoplastic Cells, CirculatingChemotherapy EffectNCT05326295Hunan Cancer Hospital1,000
Completed
Not Applicable
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast CancerLocally Advanced Breast CancerMetastatic (Stage IV) Breast CancerStage III-IV Breast Cancer or InflammatoryNCT01048918City of Hope Medical Center280
Unknown
Not Applicable
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung CancerNon Small Cell Lung CancerNCT03195569Qilu Pharmaceutical Co., Ltd.15
Unknown
Phase 2
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT02029209Chia Tai Tianqing Pharmaceutical Group Co., Ltd.110
Completed
Not Applicable
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC PatientsNasopharyngeal NeoplasmsNCT02505139Sun Yat-sen University166